News Channels

04 May 2017 BioPharmX Reports Positive Topline Results of BPX-01 Topical Minocycline for Acne
04 May 2017 Theratechnologies Partner Submits Biologics License Application for HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
04 May 2017 Poxel Announces Positive Top Line Results for Imeglimin Phase 2b Study in Japan for the Treatment of Type 2 Diabetes
04 May 2017 Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
04 May 2017 Hookipa Biotech Presents Positive Data from Phase 1 First-In-Human Trial of Vaccine Against Cytomegalovirus
03 May 2017 Pluristem Announces Promising Results from Non-Human Primate Pilot Study of PLX-R18 in Acute Radiation Syndrome
03 May 2017 Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics
03 May 2017 NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe
03 May 2017 Stainwei Granted US Patent for anti-VEGF Monoclonal Antibody and its anti-PD-1 mAb demonstrating prolonged anti-tumor activity in pre-clinical studies
03 May 2017 BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA
03 May 2017 Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH
03 May 2017 Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection
03 May 2017 Bonti Announces Hot Topics Presentation of Phase 2a Interim Clinical Data at The Aesthetic Meeting 2017
03 May 2017 Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist RGT100 and Appoints Eugen Leo as Chief Medical Officer
03 May 2017 Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritis
03 May 2017 Selecta Biosciences Obtains License for Recombinant Immunotoxin LMB-100 from National Cancer Institute (NCI) for Pancreatic Cancer, Mesothelioma and Other Cancers
03 May 2017 ImmunGene Regains Antibody-Interferon Fusion Product Candidates from Valor Biotherapeutics
03 May 2017 Stealth BioTherapeutics Initiates Phase 1/2 Trial of SBT-20 in Patients With Early Stage Huntington's Disease
03 May 2017 Concert Pharmaceuticals Initiates CTP-543 Phase 2 Trial in Alopecia Areata
03 May 2017 bluebird bio Enters Lentiviral Vector Patent License Agreement with GlaxoSmithKline for Commercialization of Gene Therapies

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing